Ceftobiprole medocaril

• Autores: Raúl Méndez, Ana Latorre, Paula González Jiménez
• Localización: Revista Española de Quimioterapia, ISSN-e 0214-3429, Vol. 35, Nº Extra 1, 2022, págs. 25-27
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 mg every 8 h in 2-hour infusions. Various clinical trials have demonstrated its usefulness in the treatment of community-acquired pneumonia and nosocomial pneumonia, with the exception of ventilator-associated pneumonia. In summary, it is a very useful antibiotic for the treatment of pneumonia.